Our library of drug research abstracts drawn from the medical literature is updated on a regular schedule, and you can be assured that new ultravate research articles will be listed here shortly after becoming available to us.
Related Sponsors
Medical research on ultravate
A degradation product of halobetasol propionate: characterization and structure.
Steroids. 2007 Oct; 72(11-12): 787-91
Cravotto G, Giovenzana GB, Masciocchi N, Palmisano G, Volante P
Degradation of halobetasol propionate was observed in the presence of bases. A single cyclization product was isolated and fully characterized by MS, NMR and X-ray crystallography.
Am J Med. 2007 Jul; 120(7): 589-90
Rashid RM, Salah W, Keuer EJ
Sebaceous hyperplasia of the vulva: case report and review of the literature.
J Low Genit Tract Dis. 2006 Jan; 10(1): 55-7
Malliah R, Gilhooly P, Lambert WC, Heller DS
Sebaceous hyperplasia is a cutaneous lesion consisting of soft, yellow, papular lesions usually occurring on the face in elderly patients. The occurrence of the lesion on the vulva is exceptionally rare. We were able to identify only three cases reported in the literature. We report a case of sebaceous hyperplasia of the vulva with an unusual presentation.
Topical halobetasol propionate in the treatment of plaque psoriasis: a review.
Am J Clin Dermatol. 2005; 6(5): 311-6
Rivera AM, Hsu S
Halobetasol propionate (HP) 0.5% ointment and cream are class I topical corticosteroids. We review the efficacy and tolerability of HP for treatment of plaque psoriasis in the English language literature. The efficacy of HP ointment and cream is consistently superior to other super-potent topical corticosteroids. Local adverse events associated with topical HP are similar to those experienced with other super-potent corticosteroids. Combination therapy with calcipotriene (calcipotriol) and tazarotene appears to be superior to monotherapy with topical HP.
Class I topical corticosteroid use by psoriasis patients in an academic practice.
J Dermatolog Treat. 2004 Jul; 15(4): 235-8
Pearce DJ, Spencer L, Hu J, Balkrishnan R, Fleischer AB, Feldman SR
BACKGROUND: Psoriasis is a chronic skin disorder that can have a profound impact on the quality of life of patients. The treatment of psoriasis is complicated by the availability of numerous topical agents, systemic agents, and phototherapy. Of the topical preparations available, the ultra-high potency, or Class I steroids, have an important role in treating psoriasis. Their use is most appropriate for the treatment of plaques in regions excluding the face, axilla, groin and genitals. OBJECTIVE: The purpose of this study was to examine the prescribing patterns of Class I topical corticosteroids within a large academic dermatology practice for patients with all types of psoriasis. METHODS: A retrospective chart review of 650 patients with psoriasis from an academic dermatology practice was performed. Class I steroid use was defined as those patients who were observed to be currently using clobetasol propionate, halobetasol propionate, diflorasone, or augmented betamethasone dipropionate. RESULTS: A total of 79% of patients were prescribed topical steroids of any class while 46% of patients were prescribed a Class I steroid. In all, 58% of patients who received topical steroid therapy received a Class I agent; 11% of patients prescribed Class I steroids also received systemic therapy for their psoriasis. Conversely, 35% of patients who received systemic therapy were also receiving Class I topical therapy. DISCUSSION: In our department, Class I topical steroids are commonly used in the treatment of psoriasis. The superpotent topicals are often used as an adjunct to systemic therapy and will likely remain a mainstay of psoriasis therapy.
Ultrapotent topical corticosteroid treatment of hemangiomas of infancy.
J Am Acad Dermatol. 2005 Feb; 52(2): 281-6
Garzon MC, Lucky AW, Hawrot A, Frieden IJ
BACKGROUND: Superficial cutaneous hemangiomas of infancy represent a therapeutic challenge. Two small case series using ultrapotent topical corticosteroids for periocular hemangiomas were reported in the ophthalmologic literature. The use of this therapy for hemangiomas of infancy at other sites on the body has not been reported. OBJECTIVE: We sought to assess the clinical effects of short-term application of ultrapotent topical corticosteroids for the treatment of hemangiomas of infancy. METHODS: The records of 34 infants with proliferating hemangiomas of infancy that were treated with ultrapotent topical steroids were reviewed retrospectively. Treatment response was based on: (1) cessation of growth; (2) shrinkage or flattening of the lesion; and (3) lightening of the surface color. Lesions demonstrating responses of two of the three criteria were judged to have good response; one criterion, partial response; and no improvement, no response. RESULTS: Of the patients, 35% demonstrated good response, 38% partial response, and 27% no response. CONCLUSIONS: Hemangiomas in 74% of the infants demonstrated either good or partial response to treatment with ultrapotent topical corticosteroids. Of the responders, the majority reported cessation of growth before what would have been expected for their age. Improvement varied, with thinner superficial hemangiomas demonstrating better cosmetic improvement than thicker lesions.
Vitamin D and topical therapy.
Cutis. 2002 Nov; 70(5 Suppl): 5-8
Lebwohl M
A sequential therapy regimen involving an initial clearing phase of daily applications of calcipotriene 0.005% ointment and halobetasol 0.05% ointment for 2 weeks, followed by halobetasol applied twice daily on weekends and calcipotriene applied twice daily on weekdays, has been shown to be effective in the management of chronic plaque psoriasis. As a clearing regimen, the combined use of halobetasol and calcipotriene for 2 weeks was superior to monotherapy with either agent. Subsequently, the use of halobetasol on weekends and calcipotriene on weekdays allowed 76% of patients to stay in remission for up to 6 months, compared with 40% of patients who applied halobetasol on weekends only and placebo on weekdays. Calcipotriene can be inactivated when mixed with some topical preparations; however, halobetasol propionate 0.05% ointment and cream have been shown to be compatible with calcipotriene for up to 2 weeks. The compatibility of calcipotriene and halobetasol permits the use of these agents together.
Int J Dermatol. 2002 Nov; 41(11): 775-7
Krishnan RS, Angel TA, Roark TR, Hsu S
Adv Nurse Pract. 2001 Dec; 9(12): 31-4, 74
Sinni-McKeehen BJ, Hazzard EF
J Pharm Biomed Anal. 2002 Mar 1; 27(6): 889-99
Mostafa AA, Bebawy LI, Refaat HH
Two spectrophotometric procedures are described for the determination of clobetasol propionate(I), halobetasol propionate(II) (corticosteroids) and quinagolide hydrochloride(III) (prolactin inhibitor). For corticosteroid drugs, the procedures are based on the formation of phenyl hydrazones of the corticosteroids which are subsequently subjected to charge transfer complexation reaction with either 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) as pi-acceptor or with iodine as sigma-acceptor. Prolactin inhibitor was reacted directly with the previous reagents. The molar ratios of the reactants were established and the experimental conditions were studied giving maximum absorption at 588 and 290 nm with DDQ and iodine methods, respectively for the three drugs. The concentration ranges were 20-150,50-300, and 20-80 microg ml(-1) in DDQ method for (I), (II), and (III), respectively and 13-20,15-40, and 8-32 microg ml(-1) in iodine method for (I), (II) and (III), respectively.